Bertha Coombs is a reporter for CNBC, covering financial markets, business news stories and health care throughout the business day. She is based at the Nasdaq Marketsite in Times Square.
Her health care coverage at CNBC has ranged from covering the implementation of the Affordable Care Act and the failed launch of the Obamacare health insurance exchanges, to how cancer researchers are using IBM's Watson to improve cancer care, and how doctors are using mobile technology to treat patients in their own homes. She also covered the devastation of Hurricane Katrina in New Orleans, the impact of the financial crisis of 2008, and reported on the oil markets from the floor of the New York Mercantile exchange.
Before joining CNBC, Coombs was a reporter and anchor for the pioneering online business network, Yahoo Finance Vision, and served as a freelance reporter for the former CNNfn financial network. Prior, she served as a reporter for ABC News One, and a substitute anchor for "World News Now" and "World News This Morning."
She began her career in general news, with previous reporting and anchoring positions at WABC-TV in New York, WPLG-TV in Miami and WFSB-TV in Hartford, Connecticut.
Coombs is a graduate of Yale University and was awarded the Leo Beranek Reporter Training Fellowship at WCVB-TV in Boston. Born in Havana, Cuba, she speaks fluent Spanish.
Follow Bertha Coombs on Twitter @BerthaCoombs
As debate rages over costly drugs like Gilead's Solvadi, patients caution: Treatment is priceless.
Express Scripts' Steve Miller has launched a crusade on high-priced specialty drugs. He calls the $84,000 price tag on Gilead Science's new hepatitis C drug Sovaldi a case of unfair pricing at its worst. "We have never had a single product that has been such a threat to the payer community," argued the chief medical officer of the nation's largest pharmacy benefit company. "If we treat everyone it would be $300 billion." Bertha Coombs interviews Dr. Miller at Express Scripts' pharmacy headquarters in Saint Louis.